AgencyRx for Novartis's Femara
Pharmaceutical Executive
In its campaign for Novartis Oncology's Femara, an aromatase inhibitor (AI), AgencyRx developed simple and haunting creative by keeping science as the focal point. "Its simplicity is very powerful. But at the same time, simplicity doesn't belittle it," says Michael Schreiber, managing partner, creative director. "It makes it that much more devastating."
THIS IS BREAST CANCER
AgencyRx
BRAND Femara CLIENT Novartis Oncology FROM LEFT: Michael Schreiber, managing partner, creative director, copy; Sarah Katz, art supervisor; Ralph Skorge, managing partner, creative director, art; Pamela Ringstrom, copy supervisor
In its campaign for Novartis Oncology's Femara, an aromatase inhibitor (AI), AgencyRx developed simple and haunting creative by keeping science as the focal point. "Its simplicity is very powerful. But at the same time, simplicity doesn't belittle it," says Michael Schreiber, managing partner, creative director. "It makes it that much more devastating."
The goal was to raise awareness about distant metastases and illustrate how cancer that originates in the breast can travel. "We wanted to make sure that doctors understood the nature of breast cancer and the importance of therapy that would reduce the risk of a distant recurrence," says Schreiber. "We created this very stark, attention-grabbing message."
The ad underscored Femara's unique benefits—a must to compete against the market leader in the category. Originally created as a one-time ad, "This is..." used iconic imagery to form the basis of a new global professional campaign for Femara. Aimee Roca, vice president, account supervisor, credits response of the Novartis Oncology team and physicians for the ad's global success.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
